Antiparasitic drugs are utilized to address various types of infections caused by a wide array of parasites. Parasites are small organisms that reside on or inside humans and animals. There are numerous antiparasitic drugs available, each designed to target a specific parasite. Parasitic infections can arise from a multitude of parasites, with the three main types being ectoparasites, helminthes, and protozoa. Antiparasitic drugs play a crucial role in treating these infections. For example, anticestodal drugs are effective against tapeworms, antitrematodal drugs target flukes, antinematodal drugs are designed to combat roundworms, and antimalarial agents are employed in the treatment of malaria. Additionally, there are specific antiparasitic drugs such as antibabesial agents for Babesiosis, antiamoebic agents for amoebic infections, trypanocidal agents for trypanosomiasis, antileishmanial agents for leishmaniasis, antiscabietic agents for scabies, and pediculicides for lice infestations. These different classes of antiparasitic drugs help address the varied range of parasitic infections and play a vital role in the overall management and treatment of these conditions.

Market Dynamics

Initiatives and campaigns by governments, non-profit organizations, and market players like Novartis are underway to promote the widespread use of antiparasitic drugs and enhance the treatment of tropical diseases, including parasitic illnesses such as malaria, leishmaniasis, and Chagas disease. These efforts aim to increase the demand for antiparasitic drugs and consequently drive the growth of the global antiparasitic drugs market in the foreseeable future. For instance, in October 2021, the U.S. President's Malaria Initiative (PMI) introduced a new five-year strategy called 'End Malaria Faster'. The primary objective of this strategy is to eliminate malaria within a generation, aligning with global targets of saving over 4 million lives and preventing 1 billion cases by 2025. The five-year PMI strategy focuses on reducing health disparities, enhancing disease surveillance, and continuing to save lives. These proactive measures by various stakeholders, such as governments and organizations like Novartis, in combating parasitic diseases and promoting the use of antiparasitic drugs demonstrate a concerted effort to address the burden of these conditions and improve public health outcomes.

Key features of the study:

• This report provides in-depth analysis of the global antiparasitic drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global antiparasitic drugs market based on the following parameters– company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Merck KGaA, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Cadila Pharmaceuticals, Watson International Limited, Vivaldis, Glenmark Pharmaceuticals Limited, Viatris Inc., Novartis AG, AdvaCare Pharma, Lupin, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global antiparasitic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antiparasitic drugs market

Detailed Segmentation:

• Global Antiparasitic Drugs Market, By Product Type:
  • Anthelmintics
    • Anticestodal Drugs
    • Antitrematodal Drugs
    • Antinematodal Drugs
  • Antiprotozoal Agents
    • Antimalarials Agents
    • Antibabesial Agents
    • Antiamoebic Agents
    • Others (Trypanocidal Agents, Antileishmanial Agents, etc.)
  • Ectoparasiticide
    • Antiscabietic Agents
    • Pediculicides
• Global Antiparasitic Drugs Market, By Route of Administration:
  • Oral
  • Injectable
  • Topical
• Global Antiparasitic Drugs Market, By Application:
  • Human Health
  • Animal Health
  • Crop Health
• Global Antiparasitic Drugs Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Merck KGaA.
  • GlaxoSmithKline plc.
  • Reddy’s Laboratories Ltd
  • Cipla Limited
  • Cadila Pharmaceuticals
  • Watson International Limited
  • Vivaldis
  • Viatris Inc.
  • Novartis AG
  • AdvaCare Pharma
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals Limited